Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 9/30/2021 | 6/30/2021 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $100 | $232 | $316 | $322 |
| - Cash | $38 | $56 | $72 | $92 |
| + Debt | $22 | $22 | $21 | $21 |
| Enterprise Value | $83 | $198 | $266 | $250 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 373.1% | -50.7% | -29% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$19 | -$22 | -$23 | -$22 |
| % Margin | -3,852.2% | -20,944.2% | -10,711.4% | -7,325.3% |
| Net Income | -$21 | -$22 | -$25 | -$24 |
| % Margin | -4,292.5% | -21,626% | -11,655.5% | -7,994.9% |
| EPS Diluted | -0.001 | -0.53 | -0.58 | -0.6 |
| % Growth | 99.9% | 8.6% | 3.3% | – |
| Operating Cash Flow | -$17 | -$16 | -$20 | -$24 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$18 | -$16 | -$20 | -$24 |